News

 

12.19.2008 James M. Burns Comments on Recent Lawsuit by Federal Trade Commission James M. Burns commented on a recent lawsuit filed by the Federal Trade Commission against Ovation Pharmaceuticals. The FTC is accusing Ovation Pharmaceuticals of unlawfully acquiring the rights to a congenital heart defect treatment, NeoProfen.

Please click the file above to read the article...